Prognostic score models for acquired resistance to frontline anti-programmed cell death protein 1/programmed death-ligand 1 therapy in metastatic non-small-cell lung cancer.

ABSTRACT:

Background

Acquired resistance (AR) to immunotherapy following initial response occurs frequently in metastatic non-small-cell lung cancer (mNSCLC). We developed and validated easy-to-apply prognostic score models to identify patients with mNSCLC at greater risk of AR to frontline (1L) anti-programmed cell death protein 1/programmed death-ligand 1 [anti-PD-(L)1] therapy.

Materials and methods

Electronic health records of patients with mNSCLC who responded to 1L anti-PD-(L)1 (diagnosed 2015-2023) in the ConcertAI Patient360™ database were analyzed. Multivariable Cox models (monotherapy versus combination) assessing association between baseline prognostic factors and real-world duration of response (rwDoR) were used to develop prognostic scores and stratify patients into low-

SUBMITTER: Murray JC 

PROVIDER: S-EPMC12836523 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature